0001571049-16-011637.txt : 20160210 0001571049-16-011637.hdr.sgml : 20160210 20160210163105 ACCESSION NUMBER: 0001571049-16-011637 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160210 DATE AS OF CHANGE: 20160210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36745 FILM NUMBER: 161406139 BUSINESS ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631-240-8800 MAIL ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 10-Q 1 t1600034_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36745

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware	59-2262718
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

50 Health Sciences Drive
Stony Brook, New York	11790
(Address of principal executive offices)	(Zip Code)

631-240-8800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

o Yes x No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o	Accelerated filer o
Non-accelerated filer o	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o Yes x No

At February 5, 2016, the registrant had 24,072,092 shares of common stock outstanding.

Applied DNA Sciences, Inc.

Form 10-Q for the Quarter Ended December 31, 2015

Table of Contents


		Page
PART I - FINANCIAL INFORMATION

Item 1 - Condensed Consolidated Financial Statements (unaudited)		1

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

Item 3 - Quantitative and Qualitative Disclosures About Market Risk		16

Item 4 - Controls and Procedures		17

PART II - OTHER INFORMATION

Item 1 – Legal Proceedings		18

Item 1A – Risk Factors		18

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds		18

Item 3 – Defaults Under Senior Securities		18

Item 4 – Mine Safety Disclosures		18

Item 5 – Other Information		18

Item 6 - Exhibits		19

Part I - Financial Information

Item 1 - Financial Statements.

APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2015			September 30, 2015
	(unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	12,382,907		$	7,312,184
Accounts receivable, net of allowance of $7,140 at December 31, 2015 and September 30, 2015		3,923,997			3,929,517
Prepaid expenses and other current assets		187,355			293,351
Total current assets		16,494,259			11,535,052

Property, plant and equipment, net of accumulated depreciation of $955,765 at December 31, 2015 and $852,867 at September 30, 2015		561,912			572,107

Other assets:
Long term accounts receivables		1,500,000			1,500,000
Deposits		58,488			62,988
Goodwill		285,386			285,386
Intangible assets, net of accumulated amortization of $284,816 and $238,368 at December 31, 2015 and September 30, 2015, respectively		1,584,473			1,598,779

Total Assets	$	20,484,518		$	15,554,312

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable and accrued liabilities	$	2,110,995		$	2,385,006
Deferred revenue		57,526			282,050
Total current liabilities		2,168,521			2,667,056


Long term accounts payable		320,400			320,400

Total liabilities		2,488,921			2,987,456

Commitments and contingencies

Stockholders’ Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2015 and September 30, 2015		—			—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2015 and September 30, 2015		—			—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2015 and September 30, 2015		—			—
Common stock, par value $0.001 per share; 500,000,000 shares authorized at December 31, 2015 and September 30, 2015; 24,072,092 and 21,504,578 shares issued and outstanding as of December 31, 2015 and September 30, 2015, respectively		24,073			21,505
Additional paid in capital		232,539,203			224,186,760
Accumulated deficit		(214,567,679	)		(211,641,409	)
Total stockholders’ equity		17,995,597			12,566,856

Total Liabilities and Stockholders’ Equity	$	20,484,518		$	15,554,312

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended December 31,
	2015			2014

Revenues	$	1,324,114		$	1,241,802

Operating expenses:
Selling, general and administrative		3,554,362			4,671,490
Research and development		471,934			278,288
Depreciation and amortization		218,346			109,726

Total operating expenses		4,244,642			5,059,504

LOSS FROM OPERATIONS		(2,920,528	)		(3,817,702	)

Other income (expense):
Interest income (expense), net		2,845			(31,875	)
Other (expense) income, net		(8,587	)		(3,685	)
Loss on conversion of promissory notes		—			(980,842	)
Loss on change in fair value of warrant liability		—			(2,994,540	)

Net loss before provision for income taxes		(2,926,270	)		(7,828,644	)

Provision for income taxes		—			—

NET LOSS	$	(2,926,270	)	$	(7,828,644	)

Net loss per share-basic and diluted	$	(0.13	)	$	(0.51	)

Weighted average shares outstanding-
Basic and diluted		22,542,176			15,456,566

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three Months Ended December 31,
	2015			2014

Cash flows from operating activities:
Net loss	$	(2,926,270	)	$	(7,828,644	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		218,346			109,726
Stock based compensation expense		396,991			1,998,524
Change in fair value of warrant liability		—			2,994,540
Loss on conversion of promissory notes		—			980,842
Common stock issued for consulting services		58,120			—
Bad debt expense		10,000			2,779
Change in operating assets and liabilities:
Accounts receivable		(4,480	)		(282,502	)
Prepaid expenses and other current assets and deposits		71,896			(18,102	)
Accounts payable and accrued liabilities		(320,825	)		(253,997	)
Deferred revenue		(224,524	)		(59,001	)
Net cash used in operating activities		(2,720,746	)		(2,355,835	)

Cash flows used in investing activities:
Purchase of property plant and equipment		(51,795	)		(30,825	)
Purchase of intangible assets		(14,301	)		—
Net cash used in investing activities		(66,096	)		(30,825	)

Cash flows from financing activities:

Net proceeds from sale of common stock and warrants		7,853,155			7,956,050
Proceeds from the exercise of warrants		4,410			—
Purchase and cancelation of previously issued warrants		—			(4,090,952	)

Net cash provided by financing activities		7,857,565			3,865,098

Net increase in cash and cash equivalents		5,070,723			1,478,438
Cash and cash equivalents at beginning of period		7,312,184			1,393,132
Cash and cash equivalents at end of period	$	12,382,907		$	2,871,570

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	$	—		$	—
Cash paid during period for taxes	$	—		$	—

Non-cash investing and financing activities:
Common stock issued for cashless exercise of options and warrants	$	49		$	—
Property, plant and equipment acquired, and included in accounts payable	$	40,908		$	181,104
Intangible assets acquired, and included in accounts payable	$	17,841		$	—
Issuance of options to settle accrued liability	$	42,335		$	—

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying condensed consolidated financial statements as of December 31, 2015 and for the three month periods ended December 31, 2015 and 2014 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended December 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2016. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2015 and footnotes thereto included in the Annual Report on Form 10-K, of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC.

The condensed consolidated balance sheet as of September 30, 2015 contained herein has been derived from the audited consolidated financial statements as of September 30, 2015, but does not include all disclosures required by GAAP.

Business and Basis of Presentation

The Company is a Delaware corporation, which was initially organized in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, the Company reincorporated in the State of Nevada, and in 2002, the Company changed its name to its current name, Applied DNA Sciences, Inc. In December 2008, the Company reincorporated from Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2015 and September 30, 2015, the Company recorded deferred revenue of $57,526 and $282,050, respectively.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Revenue Recognition, continued

Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of $504,349 from these contract awards during the three month period ended December 31, 2015 and $449,647 for the three month period ended December 31, 2014.

The Company recognizes the revenue under its cotton customer contracts when the product has been shipped, as there is no right of return under these arrangements. The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company is the primary obligor and if it has general inventory risk. The Company does not have any general inventory risk and is not the primary obligor as it relates to the marketing portion of the tagging fee. With respect to the Company’s mutual license agreement with Himatsingka America Inc. (formerly known as Divatex Home Fashion, Inc.) (“Himatsingka”), the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that the circumstances as they relate to Himatsingka’s portion of the tagging fee are more consistent with those key indicators that support net revenue reporting. In addition, the nature of some of the Company’s cotton contracts includes extended payment terms that will result in a longer collection period and slower cash inflows. As a result, $1,500,000 of revenue recognized during the fiscal year ended September 30, 2015 under the Company’s memorandum of understanding with Louis Dreyfus Commodities is included in long-term accounts receivable as of December 31, 2015 and September 30, 2015. The cotton ginning season in the United States takes place between September and December each year, therefore, revenues from these contracts may be seasonal.

Use of Estimates

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three month periods ended December 31, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Net Loss Per Share, continued

Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three month periods ended December 31, 2015 and 2014 are as follows:

	2015		2014
Warrants		7,324,727		4,470,502
Employee options		3,890,420		3,777,888
		11,215,147		8,248,390

Stock Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2015 included an aggregate of 73%, from three customers. These three customers accounted for approximately 92% of the Company’s total accounts receivable, of which $1,500,000 is classified as long term accounts receivable at December 31, 2015.

The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2014 included an aggregate of 53% from two customers. These two customers accounted for approximately 74% of the Company’s total accounts receivable at December 31, 2014.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements

In November 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes" ("ASU 2015-17"). This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position. ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016. This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. Early application is permitted as of the beginning of the interim or annual reporting period. The Company is currently evaluating the impact of the adoption of this pronouncement on its balance sheet, although it does not expect the pronouncement to have a significant impact.

In September 2015, the FASB issued Accounting Standards Update 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”). The FASB issued ASU 2015-16 to simplify US GAAP to require that the acquirer record, in the same period’s financial statements, the effect of changes to provisional, measurement period amounts calculated as if the accounting had been completed at the acquisition date and disclose the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This guidance is effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The Company does not believe that this updated standard will have a material impact on its condensed consolidated financial statements.

In August 2014, FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.

In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN

The Company has recurring net losses, which have resulted in an accumulated deficit of $214,567,679 as of December 31, 2015. The Company incurred a net loss of $2,926,270 and generated negative operating cash flow of $2,720,746 for the three month period ended December 31, 2015. However, the Company also has working capital of $14,325,738 as of December 31, 2015. At December 31, 2015 the Company had cash and cash equivalents of $12,382,907. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. Historically, the Company has financed its operations principally from the sale of equity securities. On November 23, 2015, the Company closed a registered direct public offering of common stock and a concurrent private placement of warrants to purchase common stock, for aggregate gross proceeds of approximately $8,750,000, before deducting placement agent fees and offering expenses (See Note D).

The Company expects to finance operations and capital expenditures primarily through cash received from the November 2015 public offering and concurrent private placement as well as cash flows provided by operating activities provided that it will achieve a sufficient level of future revenues. The Company estimates that its cash and cash equivalents are sufficient to fund operations for the next twelve months.

The Company may require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses.

As a result of the Company's inability to file with the SEC certain audited historical financial statements relating to the assets of Vandalia Research, Inc. acquired in September 2015 by the date on which they were required to be filed, the Company is currently ineligible to use Form S-3, a streamlined registration form, to register securities for at least twelve calendar months and it would not regain the use of Form S-3 unless the Company was able to subsequently file these audited historical financial statements. Moreover, until the Company has filed the audited historical financial statements, it would be unable to use Form S-1 or other SEC forms to register securities as required for a public offering and would be unable to conduct offerings in private placements under Rule 505 or 506 of Regulation D to any purchasers who are not accredited investors. Therefore, until such time as the Company is able to conduct a public offering, if it determines it to be necessary or advisable to raise additional capital, the Company would need to issue securities in private placements to the extent permissible by law or seek other forms of financing. These alternatives generally entail greater total costs to the Company than a public offering of securities.

NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at December 31, 2015 and September 30, 2015 are as follows:

	December 31, 2015 (unaudited)		September 30, 2015
Accounts payable	$	1,598,934	$	1,237,973
Accrued salaries payable		471,114		1,002,743
Other accrued expenses		40,947		144,290
Total	$	2,110,995	$	2,385,006

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE D - CAPITAL STOCK

On November 23, 2015, the Company entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,500,000 shares of common stock at a price of $3.49 per share in a registered direct public offering. In a concurrent private placement, the Company sold warrants to purchase 1,250,000 shares of its common stock at a price of $0.01 per warrant, with an exercise price of $4.30 per share. The warrants will be exercisable beginning six months following the closing date of the private placement and will expire five years from the date on which they become exercisable. The warrants provide each warrant holder the right, at the warrant holder's election, to exercise by means of a cashless exercise feature. The gross proceeds to the Company from this registered direct offering and concurrent private placement were $8.75 million and net proceeds after deducting the placement agent fees and offering expenses were approximately $7.9 million.

In connection with the closing of the registered direct public offering and the concurrent private placement, as partial compensation, on November 25, 2015, the Company granted warrants to purchase 50,000 shares of common stock to its placement agent. These warrants have an exercise price of $4.01 (115% of the public offering price), subject to adjustment as set forth therein, will be exercisable beginning six months following the closing date of the private placement and expire at 5:00 PM (Eastern Standard Time) on November 25, 2020. These warrants provide the placement agent the right, at the placement agent’s election, to exercise by means of a cashless exercise feature.

NOTE E - STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.

Transactions involving warrants (see Note D) are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2015		6,027,654		$	3.54
Granted		1,300,000			4.29
Exercised		(1,260	)		(3.50	)
Cancelled or expired		(1,667	)		(10.74	)
Balance at December 31, 2015	$	7,324,727		$	3.67

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE F - STOCK OPTIONS AND WARRANTS (continued)

Employee Stock Options

In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008, 2012 and 2015, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,833,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.

The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options to purchase shares of common stock and an award of shares of common stock. As of December 31, 2015 a total of 269,752 shares have been issued and options to purchase 4,666,469 shares have been granted under the Incentive Plan.

Transactions involving stock options issued to employees are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2015		3,458,905		$	4.74
Granted		531,523			3.04
Exercised		(75,000	)		(2.86	)
Cancelled or expired		(25,008	)		(4.20	)
Outstanding at December 31, 2015		3,890,420		$	4.26
Vested at December 31, 2015		2,819,006		$	4.23		$	0.97
Non-vested at December 31, 2015		1,071,415					$	0.87

During the three month period ended December 31, 2015, the Company issued an aggregate of 531,523 options to employees and non-employee board of director members. Included in these grants were 160,000 options granted to executives.

The fair value of options granted during the three month periods ended December 31, 2015 and 2014 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:

	Three Months Ended December 31, 2015			Three Months Ended December 31, 2014
Stock price	$	3.04		$	2.84
Exercise price	$	3.04		$	2.84
Expected term, years		6.10			4.86
Dividend yield		—	%		—	%
Volatility		130	%		132	%
Risk free rate		1.8	%		1.58	%

The Company recorded $396,991 and $1,998,524 as stock compensation expense for the three month periods ended December 31, 2015 and 2014, respectively. As of December 31, 2015, unrecorded compensation cost related to non-vested awards was $3,402,145 which is expected to be recognized over a weighted average period of approximately 2.35 years. The weighted average grant date fair value per share for options granted during the three month period ended December 31, 2015 was $2.71.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015
(unaudited)

NOTE G - COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. Total rent expense for the three month periods ended December 31, 2015 and 2014 was $144,716 and $124,838, respectively.

Employment Agreement

The Company has an employment agreement with the Chief Executive Officer. Effective June 21, 2014, the Chief Executive Officer’s annual salary was voluntarily deferred by $50,000. This salary deferral will be accrued and repaid when the Company reaches $3,000,000 in sales for two consecutive quarters or the Company has net income at the end of any fiscal year. Effective January 1, 2015, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000. Effective January 1, 2016, the CEO's salary was increased to $400,000 pursuant to approval by the Compensation Committee of the Board of Directors.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

NOTE H - ASSET PURCHASE AGREEMENT

As disclosed in the Company's audited consolidated financial statements as of and for the fiscal year ended September 30, 2015 and footnotes thereto included in the Annual Report on Form 10-K, filed with the SEC, on September 11, 2015, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), with Vandalia Research, Inc. a West Virginia corporation ("Vandalia"), and Derek A. Gregg, Vandalia’s Chief Executive Officer and a director of Vandalia, providing for the purchase of substantially all the assets (“Assets”) of Vandalia. The Company completed the acquisition of such Assets on the same date. The purchase price for the Assets was $1,500,000, which amount was determined through arms-length negotiation. Of this amount, $500,000 was placed in an escrow account for a period of nine months following the closing to satisfy Vandalia’s indemnification obligations, of which $350,000 was released after sixty days.

The audits of the historical financial statements of Vandalia are currently still in process. The following unaudited supplemental pro forma information presents the Company's financial results as if the acquisition of Vandalia had occurred October 1, 2013:

	Three month period
	ended
	December 31, 2014
Revenue	$	1,257,844

Net loss		(8,030,404	)

Basic and diluted loss per share	$	(0.52	)

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report (including but not limited to this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. Forward-looking statements can generally be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as “can”, “may”, “could”, “should”, “assume”, “forecasts”, “believe”, “designated to”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential”, “position”, “predicts”, “strategy”, “guidance”, “intend”, “budget”, “seek”, “project” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future.

We believe it is important to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a variety of factors and risks, including, but not limited to, those set forth in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our condensed consolidated financial statements and notes thereto included in this Quarterly Report and those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the year ended September 30, 2015, and the following factors and risks:

our short operating history, relatively new business model and lack of significant previous revenues;

our history of net losses, which may continue, and our potential inability to achieve profitability;

the possibility that we may require additional financing, which may involve the issuance of additional shares of common stock or securities exercisable for common stock and dilute the percentage of ownership held by our current stockholders;

difficulty in obtaining, or inability to obtain, additional financing if such financing becomes necessary, including due to constraints on our ability to raise and/or increased cost of raising capital, as a result of our inability to timely file the audited historical financial statements of Vandalia Research, Inc.;

volatility in the price and/or trading volume of our common stock;

future short selling and/or manipulation of the price of our common stock;

our inability to implement our short and long-term strategies;

loss of strategic relationships;

dependence on a limited number of key customers;

lack of acceptance of our products and services by potential customers;

potential failure to introduce new products and services;

difficulty or failure in expanding our sales, marketing and support organizations and our distribution arrangements necessary to enable us to reach our goals with respect to increasing market acceptance of our products and services;

inability to continue to retain the services of Dr. Hayward, our Chief Executive Officer, or Dr. Liang, our Chief Scientific Officer;

inability to compete effectively in the industries in which we operate;

lack of success in our research and development efforts for new products;

failure to manage our growth in operations and acquisitions of new technologies and businesses;

inability to protect our intellectual property rights;

intellectual property litigation against us or other legal actions or proceedings in which we may become involved;

unauthorized disclosure of sensitive or confidential data (including customer data) and cybersecurity breaches; and

adverse changes in worldwide or domestic economic, political or business conditions.

All forward-looking statements and risk factors included in this Quarterly Report are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law. Assumptions relating to the forward-looking statements included in this Quarterly Report involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control.

Any of the assumptions underlying the forward-looking statements contained in this Quarterly Report could prove inaccurate and, therefore, we cannot assure you that the results contemplated in any of such forward-looking statements will be realized and we caution you against relying on any of the forward-looking statements contained herein.

Note

Our trademarks in the United States include SigNature® DNA, fiberTyping®, DNAnet®, digitalDNA® and Sentry. All trademarks, service marks and trade names included or incorporated by reference in this Quarterly Report are the property of their respective owners, including, without limitation, SmokeCloak®, a mark owned by MSS Professional A/S and/or its affiliates, and PimaCott™, a mark owned by Divatex Home Fashion, Inc. and/or its affiliates.

Introduction

Using biotechnology as a forensic foundation, we provide plant-based-DNA security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud, and diversion. Whether for supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success. With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our plant-based DNA technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. Through our recent acquisition of substantially all of the assets of Vandalia Research, Inc. (“Vandalia”), we are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction (“PCR”).

SigNature DNA, SigNature T DNA, fiberTyping, DNAnet®, Sentry, digitalDNA, and SmokeCloak DNA, our principal anti-counterfeiting and product authentication solutions can be used in numerous industries, including, but not limited to microcircuits and other electronics, cash-in-transit (transport and storage of banknotes), textiles and apparel, home asset marking, automotive, printing and packaging, homeland security, law enforcement, industrial materials, agrochemicals, pharmaceuticals, consumer products, and food and beverage. The large-scale production of specific DNA sequences is used in the diagnostics and reagent industries and also helps to ensure our capacity to manufacture enough DNA markers for all our current and future customers.

SigNature DNA. SigNature DNA is our platform ingredient, at the core of all our security solutions. The vehicle which carries SigNature DNA is custom designed to suit the particular application for which it is being used. Exhaustive development efforts have yielded a flexible and durable marker with all the accuracy provided by nature. SigNature DNA provides forensic power and protection for a wide array of applications. Highly secure, robust, and durable, SigNature DNA markers are an ingredient that can be used to fortify brand protection efforts; mark, track and convict criminals; and strengthen supply chain security. Custom DNA sequences can be embedded into a wide range of host carriers including ink, varnish, thread, laminates and metal coatings. These items can then be tested for the presence of SigNature DNA markers through optical screening or a forensic level authentication. Hundreds of millions of SigNature DNA markers now exist in the public domain on items ranging from consumer product packaging to microcircuits to guitars. We believe that no markers have ever been copied.

SigNature T DNA and fiberTyping. There is one common thread that runs through the global textile industry: success breeds counterfeiting and diversion. SigNature T DNA markers are used for brand protection efforts and raw material source compliance programs. For example, cotton fibers can be tagged at source, verified as “American grown” and then traced through every step of the supply chain. Our patented genotyping platform, known as “fiberTyping’, is complementary to tagging with SigNature T botanical DNA. fiberTyping cannot be used to track a specific cotton batch through the supply chain, a function which can only be accomplished by our SigNature T DNA system. fiberTyping indicates the cotton species while SigNature T DNA is used as an identifier for traceability. Its information is stored in our database, operating much like a bar code. For example, entities in the cotton industry use fiberTyping to differentiate purity or blends of higher-end Pima Extra Long Staple cotton and lower-end upland cotton, in conjunction with SigNature T DNA marking applied at the gin, for traceability to the source.

DNAnet. Recognizing that DNA-based evidence is the cornerstone of the modern era of law enforcement, we have created what we believe to be an effective crime fighting tool: DNAnet, a DNA marker that can be used to definitively link evidence and offenders to specific crime scenes and help return stolen or lost property to its rightful owner. As the crime is investigated, the fluorescing DNA marker can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict.

Sentry. Sentry intruder tagging systems help to expand and strengthen any security effort by providing a means of directly linking criminals to crimes. Each unit is designed to be unique to each store, warehouse, or sting operation, allowing the police and prosecutors to link criminals to the crimes. In the event of a crime, the fleeing offender is sprayed with an indelible, fluorescing DNA taggant. As the crime is investigated, the fluorescing DNA marker can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict. Whether deployed as an offender spray or fog in a retail location or a degradation dye in cash handling boxes, DNA markers facilitate conviction, and establish a heightened level of deterrence. While any commercial/retail establishment could benefit from the addition of a Sentry system, ideal areas of use include: banks, ATMs, pharmacies, jewelry stores, convenience stores, pawn brokers and gun shops.

SmokeCloak DNA. When deployed in pharmacies, banks, commercial or retail locations, SmokeCloak DNA helps protect staff, customers and assets. A thick and disorienting fog wards off offenders and deposits a unique, location-specific DNA marker on skin, clothing and stolen items. We believe the fog and DNA markers have no negative side effects while serving as a strong crime fighting and loss prevention tool.

digitalDNA. digitalDNA is a software platform that enables customers to manage the security of company-marked goods from point of marking to point of authentication or validation to end of life. The base platform is configurable to customer requirements which differ by vertical market, company, business process and IT environment. Basic functions offered include DNA inventory management, program training and communications, database of marked items information, associated documents and images, chain of custody and location tracking, sample authentication processing and Certificate of DNA Analysis downloads, and other administrative functions. Architected for either cloud or local operation, the system supports mobile data capture using bar codes or other technologies. Of special note is the power of embedding our proprietary DNA into tag ink or substrate as the forensic backstop for tags which can be easily copied. The system is architected as the controller and repository for other validation and authentication devices such as our multi-mode reader (prototype), and other third party devices such as DNA readers and is designed to share data with third party applications through standard interfaces.

Large-scale production of specific DNA sequences using PCR. Our Triathlon™ PCR systems allow for the large-scale production of specific DNA sequences. The systems are self-contained and modular, can work together in mass production or can be used individually throughout the world, offering the advantage of delivering DNA locally and securely. These DNA sequences are being used by customers as a diagnostic and reagent. Our secure cloud application also offers back-end features including DNA custody management, forensic sample submission, CODA (certificate of DNA authentication) issuance, customer account administration, order placement, status tracking and reporting, and online training. The cloud-based platform is designed to be customizable for the particular attributes of each customer’s business and conforms to strict security standards for ISO, PCI, and Federal Information Processing Standards. This digitalDNA platform is designed as the data management and reporting hub for devices for DNA on-site authentication and optical mark in-field validation. Market-specific configurations have been demonstrated to businesses in textiles supply chain, printing/publishing, art and collectibles and law enforcement.

Plan of Operations

General

To date, the substantial portion of our revenues have been generated from sales of our SigNature DNA and SigNature T DNA, our principal anti-counterfeiting and product authentication solutions. We expect to continue to grow revenues from sales of our SigNature DNA platform ingredient, including our Signature T DNA, DNAnet, Sentry, digitalDNA, and SmokeCloak DNA offerings as well as from large scale production of specific DNA sequences using PCR. Our developments in the textile and apparel authentication, electronics authentication, cash-in-transit, and asset protection markets have contributed to the increase in our revenues. We intend to pursue both domestic and international sales opportunities in each of these vertical markets, and select other vertical markets.

Critical Accounting Policies

See Note A to the accompanying condensed consolidated financial statements for our critical accounting policies.

Comparison of Results of Operations for the Three Month Periods Ended December 31, 2015 and 2014

Revenues

For the three month periods ended December 31, 2015 and 2014, we generated $1,324,114 and $1,241,802, respectively, in revenues. The increase in revenues in the three month period ended December 31, 2015 of $82,312 or 7% was primarily from an increase in revenue related to DNA manufacturing for the diagnostic market of $242,000, an increase of approximately $55,000 from two government contract awards and an increase in consumer asset marking sales of $60,000. These increases were partially offset by a decrease in revenue from suppliers of the Defense Logistics Agency ("DLA") due to the consolidation of our contracts with several individual suppliers of the DLA to one contract directly with the DLA as well as other decreases in revenue from military customers of approximately $200,000 and a decrease in revenue related to industrial materials of approximately $81,000.

Costs and Expenses

Selling, General and Administrative

Selling, general and administrative expenses for the three month period ended December 31, 2015 decreased by $1,117,128 or 24% from $4,671,490 for the three month period ended December 31, 2014 to $3,554,362 for the three month period ended December 31, 2015. The decrease is attributable to a decrease in stock based compensation expense of approximately $1.6 million, primarily associated with grants to employees during the three month period ended December 31, 2015 having a four year vesting period whereas the grants to employees during the three month period ended December 31, 2014 vested immediately. The decrease in stock based compensation was primarily offset by increases in accounting and legal fees of approximately $113,000 and $129,000, respectively, as well as an increase in payroll expenses of $120,000 primarily for accrued employee bonuses.

Research and Development

Research and development expenses increased to $471,934 for the three month period ended December 31, 2015 from $278,288 for the three month period ended December 31, 2014, an increase of $193,646 or 70%. This increase is primarily due to development costs incurred in relation to two government contracts as well as an increase in other laboratory supplies and materials.

Depreciation and Amortization

In the three month period ended December 31, 2015, depreciation and amortization increased by $108,620 from $109,726 for the three month period ended December 31, 2014 to $218,346 for the three month period ended December 31, 2015. This increase is attributable to $69,000 of amortized customer purchase orders acquired from Vandalia Research, Inc. (“Vandalia”) and fulfilled by the Company during the three month period ended December 31, 2015, as well as $23,000 relating to amortization expense for customer relationships and technology purchased from Vandalia during September 2015.

Loss on Change in Fair Value of Warrant Liability

Loss from change in fair value of warrant liability during the three month period ended December 31, 2014 was $2,994,540. This change in fair value related to warrants containing certain reset provisions which required us to classify them as liabilities and mark the warrants to market and record the change in fair value at each reporting period, and upon exercise as a non-cash adjustment to our current period operations.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of December 31, 2015, we had working capital of $14,325,738. For the three month period ended December 31, 2015, we generated a net cash flow deficit from operating activities of $2,720,746 consisting primarily of our loss of $2,926,270 net with non-cash adjustments of $218,346 in depreciation and amortization charges, $396,991 for stock-based compensation, $58,120 in common stock issued for consulting services, and $10,000 in bad debt expense. Additionally, we had a net decrease in operating assets of $67,416 and a net decrease in operating liabilities of $545,349. Cash used in investing activities was $66,096 for the purchase of property, plant and equipment and intangible assets. Cash provided by financing activities was $7,857,565 consisting primarily of net proceeds from the sale of common stock in the public offering and the concurrent private placement of warrants, which permit warrant holders to exercise by means of a cashless exercise feature.

At December 31, 2015, there was $1,500,000 included in long-term accounts receivable relating to a customer from the cotton industry that purchased SigNature T DNA to help secure the cotton supply chain. The nature of this contract includes extended payment terms that will result in a longer collection period and slower cash inflows, which will affect our liquidity and capital resources.

We have recurring net losses, which have resulted in an accumulated deficit of $214,567,679 as of December 31, 2015. We have incurred a net loss of $2,926,270 for the three month period ended December 31, 2015. At December 31, 2015 we had cash and cash equivalents of $12,382,907 and working capital of $14,325,738. Our current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. Historically, we have financed our operations principally from the sale of equity securities. As discussed in Note D to the accompanying condensed consolidated financial statements, on November 23, 2015, we closed a registered direct public offering of common stock and a private placement of warrants to purchase common stock, for aggregate gross proceeds of approximately $8,750,000, before deducting placement agent discounts and offering expenses (excluding proceeds from any future exercises of such warrants).

We expect to finance operations and capital expenditures primarily through the cash received from the November 2015 public offering and concurrent private placement as well as cash flows provided by operating activities provided that we achieve a sufficient level of future revenues. We estimate that our cash and cash equivalents are sufficient to fund operations and capital expenditures for the next twelve months.

We may require additional funds to complete the continued development of our products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover our operating expenses. If revenues are not sufficient to cover our operating expenses, and if we are not successful in obtaining the necessary additional financing, we will most likely be forced to reduce operations.

As a result of our inability to file with the SEC certain audited historical financial statements relating to the assets of Vandalia Research, Inc. acquired in September 2015 by the date on which they were required to be filed, we are currently ineligible to use Form S-3, a streamlined registration form, to register securities for at least twelve calendar months and we would not regain the use of Form S-3 unless we are able to subsequently file these audited historical financial statements. Moreover, until we have filed the audited historical financial statements, we would be unable to use Form S-1 or other SEC forms to register securities as required for a public offering and would be unable to conduct offerings in private placements under Rule 505 or 506 of Regulation D to any purchasers who are not accredited investors. Therefore, until such time as we are able to conduct a public offering, if we determine it to be necessary or advisable to raise additional capital, we would need to issue securities in private placements to the extent permissible by law or seek other forms of financing. These alternatives generally entail greater total costs to us than a public offering of securities and may result in increased dilution to stockholders.

We expect capital expenditures to be less than $2,000,000 in fiscal 2016. Our primary investments are expected to be in laboratory equipment to support prototyping, manufacturing, our authentication services, and outside services for our detector and reader development.

All of the real property used in our business is leased under operating lease agreements.

Subsequent Events

None.

Product Research and Development

We anticipate spending approximately $2,000,000 for product research and development activities during the next twelve months.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Item 3. - Quantitative and Qualitative Disclosures About Market Risk.

Information requested by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.

Item 4. - Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2015, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended December 31, 2015, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II - Other Information

Item 1. - Legal Proceedings.

None.

Item 1A. – Risk Factors.

You should carefully consider the risks and uncertainties described under the caption “Forward-Looking Statements” in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of this Quarterly Report and in our other filings with the SEC, including our Annual Report on Form 10-K for the year ended September 30, 2015, and our subsequent filings. The risks and uncertainties described in this Quarterly Report and in our other filings with the SEC are not the only ones facing us. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect us. If any of these risks actually materialize, our business, financial position, results of operations and cash flows could be materially adversely impacted. In that event, the market price of our common stock could decline and you may lose all or part of your investment. As further described under the caption “Forward-Looking Statements” in Part I, Item 2, this Quarterly Report also contains forward-looking statements that involve additional risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements due to the factors and risks described above or other factors.

During the fiscal quarter ended December 31, 2015, there have been no material changes in our risk factors previously disclosed under Part 1, Item 1A in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015.

Item 2. - Unregistered Sales of Equity Securities and Use of Proceeds.

On each of October 30, 2015, November 30, 2015 and December 31, 2015 we issued 5,000 shares of our common stock, aggregating 15,000 shares, to a consultant for services provided pursuant to our Incentive Plan. In addition, on December 31, 2015, we issued 3,000 shares of our common stock to a consultant for services provided pursuant to our Incentive Plan.

The foregoing issuances of common stock were exempt from registration under the Securities Act, pursuant to the exemptions from registration provided by Section 4(a)(2) of the Securities Act and/or by Rule 506 of Regulation D promulgated under the Securities Act as transactions not involving a public offering.

Item 3. – Defaults Upon Senior Securities.

None.

Item 4. – Mine Safety Disclosures.

None.

Item 5. – Other Information.

None.

Item 6. – Exhibits.

10.1	Placement Agency Agreement by and between Applied DNA Sciences, Inc. and Maxim Group LLC, dated November 23, 2015 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the Company’s Current Report on Form 8-K/A, filed November 23, 2015)

10.2	Form of Securities Purchase Agreement, dated as of November 23, 2015 (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Company’s Current Report on Form 8-K/A, filed November 23, 2015)

4.1	Form of Purchase Warrant, dated as of November 25, 2015 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed November 23, 2015)

4.2	Form of Placement Agent Warrant issued to Maxim Group LLC (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed November 23, 2015)


31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended


32.1**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

101 INS*	XBRL Instance Document

101 SCH*	XBRL Taxonomy Extension Schema Document

101 CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101 LAB*	XBRL Extension Label Linkbase Document

101 PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith.

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

Signatures

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Applied DNA Sciences, Inc.

Dated: February 10, 2016	/s/ JAMES A. HAYWARD
	James A. Hayward, Ph. D.
	Chief Executive Officer
	(Duly authorized officer and principal executive officer)

	/s/ BETH JANTZEN
Dated: February 10, 2016	Beth Jantzen, CPA
	Chief Financial Officer
	(Duly authorized officer and
	principal financial and accounting officer)

EX-31.1 2 t1600034_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, James A. Hayward, certify that:

I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: February 10, 2016

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.

EX-31.2 3 t1600034_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Beth Jantzen, certify that:

I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: February 10, 2016

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.

EX-32.1 4 t1600034_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, James A. Hayward, Chief Executive Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

●

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.


	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.
		Dated: February 10, 2016

EX-32.2 5 t1600034_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Beth Jantzen, Chief Financial Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

●

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.


	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.
		Dated: February 10, 2016

EX-101.INS 6 apdn-20151231.xml XBRL INSTANCE DOCUMENT 0000744452 2013-06-01 2013-06-15 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2014-06-21 0000744452 2014-10-01 2014-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:TwoCustomersConcentrationRiskMember 2014-10-01 2014-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:TwoCustomersConcentrationRiskMember 2014-10-01 2014-12-31 0000744452 us-gaap:WarrantMember 2014-10-01 2014-12-31 0000744452 us-gaap:EmployeeStockOptionMember 2014-10-01 2014-12-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2015-01-01 0000744452 apdn:AssetPurchaseAgreementMember apdn:VandaliaResearchIncMember 2015-09-11 0000744452 2015-09-30 0000744452 us-gaap:SeriesAPreferredStockMember 2015-09-30 0000744452 us-gaap:SeriesBPreferredStockMember 2015-09-30 0000744452 apdn:SecuritiesPurchaseAgreementMember 2015-11-23 0000744452 apdn:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2015-11-23 0000744452 apdn:SecuritiesPurchaseAgreementMember 2015-11-01 2015-11-23 0000744452 us-gaap:PrivatePlacementMember 2015-11-25 0000744452 us-gaap:PrivatePlacementMember 2015-11-01 2015-11-25 0000744452 2015-10-01 2015-12-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2015-10-01 2015-12-31 0000744452 apdn:EmployeesConsultantsAndNonEmployeeBoardOfDirectorMembersMember us-gaap:EmployeeStockOptionMember 2015-10-01 2015-12-31 0000744452 us-gaap:ExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2015-10-01 2015-12-31 0000744452 us-gaap:WarrantMember 2015-10-01 2015-12-31 0000744452 us-gaap:EmployeeStockOptionMember 2015-10-01 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:ThreeCustomersConcentrationRiskMember 2015-10-01 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:ThreeCustomersConcentrationRiskMember 2015-10-01 2015-12-31 0000744452 2015-12-31 0000744452 us-gaap:SeriesAPreferredStockMember 2015-12-31 0000744452 us-gaap:SeriesBPreferredStockMember 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:ThreeCustomersConcentrationRiskMember 2015-12-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember us-gaap:SubsequentEventMember 2016-01-01 0000744452 2016-02-05 0000744452 2014-09-30 0000744452 2014-12-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2015-09-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2015-12-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure apdn:Customer utr:sqft APPLIED DNA SCIENCES INC 0000744452 apdn --09-30 Smaller Reporting Company 24072092 10-Q 2015-12-31 false 2016 Q1

7312184

12382907

1393132

2871570

3929517

3923997

293351

187355

11535052

16494259

572107

561912

62988

58488

1598779

1584473

15554312

20484518

2385006

2110995

282050

57526

2667056

2168521

2987456

2488921

21505

24073

224186760

232539203

-211641409

-214567679

12566856

17995597

15554312

20484518

7140

852867

955765

238368

284816

0.001

10000000

0.001

500000000

21504578

24072092

21504578

24072092

1241802

1324114

4671490

3554362

278288

471934

109726

218346

5059504

4244642

-31875

2845

-3685

-8587

-980842 -2994540

-7828644

-2926270

-7828644

-2926270

-0.51

-0.13

15456566

22542176

-3817702

-2920528

109726

218346

1998524

396991

58120

2779

10000

282502

4480

18102

-71896

-253997

-320825

-59001

-224524

-2355835

-2720746

30825

51795

14301

-30825

-66096

7956050 7853155 4090952

3865098

7857565

1478438

5070723

49 181104 40908 17841

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE A — SUMMARY OF ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>General</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying condensed consolidated financial statements as of December 31, 2015 and for the three month periods ended December 31, 2015 and 2014 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended December 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2016. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2015 and footnotes thereto included in the Annual Report on Form 10-K, of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The condensed consolidated balance sheet as of September 30, 2015 contained herein has been derived from the audited consolidated financial statements as of September 30, 2015, but does not include all disclosures required by GAAP.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Business and Basis of Presentation</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is a Delaware corporation, which was initially organized in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, the Company reincorporated in the State of Nevada, and in 2002, the Company changed its name to its current name, Applied DNA Sciences, Inc. In December 2008, the Company reincorporated from Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation. </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Revenue Recognition</u> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2015 and September 30, 2015, the Company recorded deferred revenue of $57,526 and $282,050, respectively.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of $504,349 from these contract awards during the three month period ended December 31, 2015 and $449,647 for the three month period ended December 31, 2014.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognizes the revenue under its cotton customer contracts when the product has been shipped, as there is no right of return under these arrangements. The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company is the primary obligor and if it has general inventory risk. The Company does not have any general inventory risk and is not the primary obligor as it relates to the marketing portion of the tagging fee. With respect to the Company’s mutual license agreement with Himatsingka America Inc. (formerly known as Divatex Home Fashion, Inc.) (“Himatsingka”), the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that the circumstances as they relate to Himatsingka’s portion of the tagging fee are more consistent with those key indicators that support net revenue reporting. In addition, the nature of some of the Company’s cotton contracts includes extended payment terms that will result in a longer collection period and slower cash inflows. As a result, $1,500,000 of revenue recognized during the fiscal year ended September 30, 2015 under the Company’s memorandum of understanding with Louis Dreyfus Commodities is included in long-term accounts receivable as of December 31, 2015 and September 30, 2015. The cotton ginning season in the United States takes place between September and December each year, therefore, revenues from these contracts may be seasonal.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i> </i></b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><u>Use of Estimates</u></b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Net Loss Per Share</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the three month periods ended December 31, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three month periods ended December 31, 2015 and 2014 are as follows: </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2014</td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 785px;">Warrants</td> <td style="width: 46px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 157px; text-align: right;">7,324,727</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 46px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 158px; text-align: right;">4,470,502</td> <td style="width: 16px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Employee options</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3,890,420</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3,777,888</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-indent: -2in; padding-bottom: 4px; padding-left: 2in;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">11,215,147</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">8,248,390</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Stock Based Compensation</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Concentrations</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2015 included an aggregate of 73%, from three customers. These three customers accounted for approximately 92% of the Company’s total accounts receivable, of which $1,500,000 is classified as long term accounts receivable at December 31, 2015.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2014 included an aggregate of 53% from two customers. These two customers accounted for approximately 74% of the Company’s total accounts receivable at December 31, 2014.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b></b> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In November 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes" ("ASU 2015-17").   This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company is currently evaluating the impact of the adoption of this pronouncement on its balance sheet, although it does not expect the pronouncement to have a significant impact.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In September 2015, the FASB issued Accounting Standards Update 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”). The FASB issued ASU 2015-16 to simplify US GAAP to require that the acquirer record, in the same period’s financial statements, the effect of changes to provisional, measurement period amounts calculated as if the accounting had been completed at the acquisition date and disclose the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This guidance is effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The Company does not believe that this updated standard will have a material impact on its condensed consolidated financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, <font style="background-color: white;">FASB</font> issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.</p>

<div> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>NOTE E - STOCK OPTIONS AND WARRANTS</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><u>Warrants</u></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Transactions involving warrants (see Note D) are summarized as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted<br />Average <br />Exercise<br />Price Per <br />Share</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 878px;">Balance at October 1, 2015</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 151px;">6,027,654</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 150px;">3.54</td> <td style="text-align: left; width: 12px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,300,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.29</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,260</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3.50</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="border-bottom: black 2px solid;">Cancelled or expired</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(1,667</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(10.74</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Balance at December 31, 2015</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">7,324,727</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">3.67</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <div style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  </div> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><u></u> </p> <div style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><u>Employee Stock Options</u></div> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008, 2012 and 2015, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,833,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options to purchase shares of common stock and an award of shares of common stock. As of December 31, 2015 a total of 269,752 shares have been issued and options to purchase 4,666,469 shares have been granted under the Incentive Plan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Transactions involving stock options issued to employees are summarized as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted <br />Average<br />Exercise<br />Price Per<br />Share</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 502px;">Outstanding at October 1, 2015</td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 204px;">3,458,905</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 46px;">$</td> <td style="text-align: right; width: 157px;">4.74</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 31px;"> </td> <td style="text-align: left; width: 63px;"> </td> <td style="text-align: right; width: 159px;"> </td> <td style="text-align: left; width: 16px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">531,523</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.04</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(75,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2.86</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(25,008</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(4.20</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: right; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Outstanding at December 31, 2015</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,890,420</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4.26</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Vested at December 31, 2015</td> <td style="border-bottom: black 4px double;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">2,819,006</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.23</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">0.97</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Non-vested at December 31, 2015</td> <td style="border-bottom: black 4px double;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">1,071,415</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;"> </td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">0.87</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 4.5pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="widows: 1; text-transform: none; text-indent: 4.5pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="widows: 1; text-transform: none; text-indent: 4.5pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">During the three month period ended December 31, 2015, the Company issued an aggregate of 531,523 options to employees and non-employee board of director members. Included in these grants were 160,000 options granted to executives.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The fair value of options granted during the three month periods ended December 31, 2015 and 2014 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Three<br />Months<br />Ended<br />December 31, <br />2015</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Three<br />Months<br />Ended<br />December 31, <br />2014</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 928px;">Stock price</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 126px;">3.04</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 125px;">2.84</td> <td style="text-align: left; width: 12px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.04</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">2.84</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left;">Expected term, years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6.10</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.86</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">132</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk free rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.8</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.58</td> <td style="text-align: left;">%</td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company recorded $396,991 and $1,998,524 as stock compensation expense for the three month periods ended December 31, 2015 and 2014, respectively. As of December 31, 2015, unrecorded compensation cost related to non-vested awards was $3,402,145 which is expected to be recognized over a weighted average period of approximately 2.35 years. The weighted average grant date fair value per share for options granted during the three month period ended December 31, 2015 was $2.71. </div> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2014</td> <td style="padding-bottom: 2px; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 785px;">Warrants</td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 157px;">7,324,727</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 158px;">4,470,502</td> <td style="text-align: left; width: 16px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Employee options</td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">3,890,420</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">3,777,888</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="padding-bottom: 4px; padding-left: 2in;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">11,215,147</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">8,248,390</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">December 31,<br />2015<br />(unaudited)</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">September 30,<br />2015</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left; width: 928px;">Accounts payable</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 126px;">1,598,934</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 125px;">1,237,973</td> <td style="text-align: left; width: 12px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued salaries payable</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">471,114</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,002,743</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="border-bottom: black 2px solid; text-align: left;">Other accrued expenses</td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">40,947</td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">144,290</td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,110,995</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,385,006</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted<br />Average <br />Exercise<br />Price Per <br />Share</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 878px;">Balance at October 1, 2015</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 151px;">6,027,654</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 150px;">3.54</td> <td style="text-align: left; width: 12px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,300,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.29</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,260</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3.50</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="border-bottom: black 2px solid;">Cancelled or expired</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(1,667</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(10.74</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Balance at December 31, 2015</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">7,324,727</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">3.67</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted <br />Average<br />Exercise<br />Price Per<br />Share</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="border-bottom: black 2px solid;" nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 502px;">Outstanding at October 1, 2015</td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 204px;">3,458,905</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 46px;">$</td> <td style="text-align: right; width: 157px;">4.74</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 31px;"> </td> <td style="text-align: left; width: 63px;"> </td> <td style="text-align: right; width: 159px;"> </td> <td style="text-align: left; width: 16px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">531,523</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.04</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(75,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2.86</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(25,008</td> <td style="border-bottom: black 2px solid; text-align: left;">)</td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(4.20</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: right; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Outstanding at December 31, 2015</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,890,420</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4.26</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Vested at December 31, 2015</td> <td style="border-bottom: black 4px double;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">2,819,006</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.23</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">0.97</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Non-vested at December 31, 2015</td> <td style="border-bottom: black 4px double;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">1,071,415</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;"> </td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">0.87</td> <td style="border-bottom: black 4px double; text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

8248390

4470502

3777888

11215147

7324727

3890420

449647

504349

0.53

0.74

0.73

0.92

2 2 3 3 14325738

1237973

1598934

1002743

471114

144290

40947

1260

0.01

2500000

1250000

50000

4.30

4.01

1.15

8750000

6027654

7324727

1300000 1667 3.54 3.67 4.29 3.50 10.74

3458905

3890420

531523

160000

75000

25008

2819006

1071415

4.74

4.26

3.04

2.86

4.20

4.23 0.97 0.87 2.84 3.04 2.84 3.04

P4Y10M10D

P6Y1M6D

1.32

1.30

0.0158

0.018

833334

269752

4666469

3402145

P2Y4M6D

30000

P3Y

449142

124838

144716

3000000

1500000

285386

320400 320400

4410

42335 <div> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>NOTE H - ASSET PURCHASE AGREEMENT</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b> </b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">As disclosed in the Company's audited consolidated financial statements as of and for the fiscal year ended September 30, 2015 and footnotes thereto included in the Annual Report on Form 10-K, filed with the SEC, on September 11, 2015, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), with Vandalia Research, Inc. a West Virginia corporation ("Vandalia"), and Derek A. Gregg, Vandalia’s Chief Executive Officer and a director of Vandalia, providing for the purchase of substantially all the assets (“Assets”) of Vandalia. The Company completed the acquisition of such Assets on the same date. The purchase price for the Assets was $1,500,000, which amount was determined through arms-length negotiation. Of this amount, $500,000 was placed in an escrow account for a period of nine months following the closing to satisfy Vandalia’s indemnification obligations, of which $350,000 was released after sixty days.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> </p> <p style="widows: 1; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The audits of the historical financial statements of Vandalia are currently still in process. The following unaudited supplemental pro forma information presents the Company's financial results as if the acquisition of Vandalia had occurred October 1, 2013:<br /> </p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Three month period</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">ended</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">December 31, 2014</td> <td nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 1227px;">Revenue</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">1,257,844</td> <td style="text-align: left; width: 14px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(8,030,404</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left;">Basic and diluted loss per share</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(0.52</td> <td style="text-align: left;">)</td> </tr> </table> </div> 7900000 <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Three month period</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">ended</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">December 31, 2014</td> <td nowrap="nowrap"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="width: 1227px;">Revenue</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">1,257,844</td> <td style="text-align: left; width: 14px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(8,030,404</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="text-align: left;">Basic and diluted loss per share</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(0.52</td> <td style="text-align: left;">)</td> </tr> </table> </div>

3.49

1500000

500000

350000

400000 50000 50000

1257844

-8030404

-0.52 00007444522015-11-012015-11-23

8750000

8833333

2.71

EX-101.SCH 7 apdn-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - ASSET PURCHASE AGREEMENT link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ASSET PURCHASE AGREEMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - CAPITAL STOCK (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - ASSET PURCHASE AGREEMENT (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - ASSET PURCHASE AGREEMENT (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 apdn-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 apdn-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 apdn-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Preferred Stock [Member] Series A Preferred stock Series B Preferred Stock [Member] Series B Preferred stock Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable, net of allowance of $7,140 at December 31, 2015 and September 30, 2015 Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net of accumulated depreciation of $955,765 at December 31, 2015 and $852,867 at September 30, 2015 Property plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent [Abstract] Other assets: Accounts Receivable, Net, Noncurrent Long-term accounts receivable revenue recognized Long term accounts receivables Deposits Assets, Noncurrent Deposits Goodwill Finite-Lived Intangible Assets, Net Amortization on intangible assets Intangible assets, net of accumulated amortization of $284,816 and $238,368 at December 31, 2015 and September 30, 2015, respectively Net Assets Total Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total Deferred revenue Deferred revenue Deferred revenue Liabilities, Current Total current liabilities Total current liabilities Accounts Payable, Noncurrent Long term accounts payable Represents the amount related to the long term accounts payable. Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Preferred stock value Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2014 and September 30, 2013 Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, par value $0.001 per share; 500,000,000 shares authorized at December 31, 2015 and September 30, 2015; 24,072,092 and 21,504,578 shares issued and outstanding as of December 31, 2015 and September 30, 2015, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated losses Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Stockholders' Equity Attributable To Parent Balance Total stockholders' equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity Allowance for Doubtful Accounts Receivable, Current Allowance on accounts receivable (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation on property, plant and equipment (in dollars) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization on intangible assets (in dollars) Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenue, Net Revenues Sales Operating Expenses [Abstract] Operating expenses: Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Research and Development Expense Research and development Research and development expenses Research and development Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation and amortization Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) NET LOSS FROM OPERATIONS LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income (Expense), Net, Total Interest income (expense), net Interest expense, net (Note C) Interest income (expense), net Other Nonoperating Income (Expense) Other (expense) income, net Other (expense) income, net Loss On Conversion Of Promissory Notes Loss on conversion of promissory notes Represent loss on conversion of promissory notes. Loss on conversion of promissory notes Loss on conversion of promissory notes Income Loss From Change In Fair Value Of Warrant Liability Gain (loss) on change in fair value of warrant liability Loss on change in fair value of warrant liability Represent income (loss) from change in fair value of warrant liability. Change in fair value of warrant liability Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income taxes Net loss before provision for income taxes Net loss before provision for income taxes Income Tax Expense (Benefit) Provision for income taxes Income taxes (benefit) Net Income (Loss) Attributable To Parent Net loss NET LOSS NET LOSS Earnings Per Share, Basic and Diluted Net Loss per share - basic and diluted Net loss per share-basic and diluted Net (loss) per share-basic and fully diluted Net loss per share-basic and diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding- Weighted Average Number Of Shares Outstanding, Basic and Diluted Basic and diluted Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Stock based compensation expense Stock-based compensation expense Stock based compensation expense Equity based compensation Fair value of vested warrants issued for services Common Stock Issued For Consulting Services Common stock issued for consulting services This element represents amount of common stock issued for consulting services during the period. Provision for Doubtful Accounts Bad debt expense Increase (Decrease) In Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) In Accounts Receivable (Increase) decrease in accounts receivable Accounts receivable Increase (Decrease) In Prepaid Expense and Other Assets Decrease in prepaid expenses and deposits Decrease in prepaid expenses and deposits Prepaid expenses and other current assets and deposits Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities (Decrease) increase in accounts payable and accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Used In Operating Activities Operating cash flow Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows used in investing activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property plant and equipment Payments to Acquire Intangible Assets Purchase of intangible assets Net Cash Provided By (Used In) Investing Activities, Continuing Operations Cash flows from investing activities Net cash used in investing activities Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Proceeds From Sale Of Common Stock And Warrants Net proceeds from sale of common stock and warrants The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity. Net proceeds from sale of common stock and warrants Proceeds from Warrant Exercises Proceeds from the exercise of warrants Purchase And Cancelation Of Previously Issued Warrants This element represents purchase and cancelation of previously issued warrants. Purchase and cancelation of previously issued warrants Net Cash Provided By (Used In) Financing Activities, Continuing Operations Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Interest Paid Cash paid during period for interest Income Taxes Paid Cash paid during period for taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Common Stock Issued For Cashless Exercise Of Options And Warrants Common stock issued for cashless exercise of options and warrants This element represents the amount of common stock issued for cashless exercise of options and warrants. Property Plant And Equipment Acquired Included In Accounts Payable Property, plant and equipment acquired, and included in accounts payable It represents property, plant and equipment acquired, included in accounts payable. Intangible Assets Acquired Included In Accounts Payable Intangible assets acquired, and included in accounts payable Represents value of intangible assets acquired, and included in accounts payable. Issuance of options to settle accrued liability Represents the amount related to the proceeds from issuance of options to settle accrued liability. Accounting Policies [Abstract] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Business and Basis of Presentation SUMMARY OF ACCOUNTING POLICIES Liquidity And Management Plan [Abstract] Liquidity And Management Plan [Text Block] LIQUIDITY AND MANAGEMENT'S PLAN The entire disclosure about liquidity and management plan. Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Stockholders' Equity Note [Abstract] Capital Stock [Abstract] Shareholders' Equity and Share-Based Payments [Text Block] CAPITAL STOCK Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK OPTIONS AND WARRANTS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Asset Purchase Agreement [Abstract] Asset Purchase Agreement [Text Block] ASSET PURCHASE AGREEMENT Represents the entire disclosure for asset purchase agreement. Business Description and Basis of Presentation [Text Block] Business and Basis of Presentation Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock Based Compensation Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities excluded from computation of earning per share Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued liabilities Schedule Of Disclosure Transactions Of Warrants [Table Text Block] Schedule of transactions involving warrants Tabular disclosure of components of transactions of warrants. Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of transactions involving stock options issued to employees Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of fair value of options granted Asset Purchase Agreement [Table Text Block] Per forma information of company's financial results as if acquisition occurred Represents the tabular disclosure of Asset purchased. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Employee Stock Option [Member] Employee Stock Options Employee options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from diluted net loss per share Revenue Recognition, Milestone Method, Revenue Recognized Revenue for government contract awards Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales [Member] Total Revenue Accounts Receivable [Member] Accounts Receivable Major Customers [Axis] Concentration Risk Type [Axis] Name Of Major Customer [Domain] Concentration Risk Type [Domain] Three Customers Concentration Risk [Member] Three customers Reflects the percentage that revenues in the period from customer is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer. Two Customers Concentration Risk [Member] Two customers Reflects the percentage that revenues in the period from customer is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer. Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Percentage of total revenue and accounts receivable Concentration Risk Number Of Customers Number of customers It represents number of major customers in concentration risk. Working Capital Surplus Deficit Working capital It represents working capital surplus deficit. Accounts Payable, Current Accounts payable Accrued Salaries, Current Accrued salaries payable Other Accrued Liabilities, Current Other accrued expenses Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Agreement [Axis] Agreement [Axis] Information related to an agreement which represents negotiated and usually legally enforceable understanding between two or more legally competent parties. Agreement [Domain] Agreement [Domain] Information related to an agreement which represents negotiated and usually legally enforceable understanding between two or more legally competent parties. Securities Purchase Agreement [Member] Securities Purchase Agreement Represents securities purchase agreement. Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private placement Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Issued During Period, Shares, New Issues Underwritten public offering of common stock and warrants closed Number of shares issued Shares Issued, Price Per Share Share issued (Price per share) Combined offering price Share price Fair value of common stock Combined offering price Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of common stock called by warrants Number of common stock called by warrants Aggregate shares of common stock issued Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise Prices Net Proceeds After Deducting Placement Agent Fees And Offering Expenses Net proceeds after deducting placement agent fees and offering expenses Represents amount of net proceeds after deducting the placement agent fees and offering expenses. Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Exercise price percentage of public offering price Class Of Warrant Or Right, Number Of Shares [Roll Forward] Number of Shares A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Number of warrants granted Number Outstanding Number of warrants outstanding Balance at October 1, 2015 Balance, December 31, 2015 Class Of Warrant Or Right Granted Number of shares of common stock granted Granted Represents number of warrants granted to participants. Class Of Warrant Or Right Exercised Exercised Cashless exercise of warrant Represents the number of warrants exercised by participants. Exercised Class Of Warrant Or Right Forfeitures and Expirations Cancelled or expired Represents the number of warrants that were either cancelled or expired. Cancelled or expired Class Of Warrant Or Right, Weighted Average Price Per Share [Roll Forward] Weighted Average Exercise Price Per Share A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Weighted Average Price Per Share Warrant Outstanding Balance at October 1, 2015 Balance, December 31, 2015 Represents weighted average exercise price per share or per unit of warrants or rights outstanding. Weighted Average Price Per Share Warrant Granted Granted Represents weighted average exercise price per share or per unit of warrants or rights granted. Weighted Average Price Per Share Warrant Exercised Exercised Represents weighted average exercise price per share or per unit of warrants or rights exercised. Exercised Weighted Average Price Per Share Warrant Cancelled Or Expired Cancelled or expired Represents weighted average exercise price per share or per unit of warrants or rights Cancelled or expired. Cancelled or expired Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Stock Plan 2005 [Member] Incentive Stock Plan 2005 Incentives awarded to employees for meeting certain performance targets. EX-101.PRE 11 apdn-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2015	Feb. 05, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	0000744452
Trading Symbol	apdn
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,072,092
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Current assets:
Cash and cash equivalents	$ 12,382,907	$ 7,312,184
Accounts receivable, net of allowance of $7,140 at December 31, 2015 and September 30, 2015	3,923,997	3,929,517
Prepaid expenses and other current assets	187,355	293,351
Total current assets	16,494,259	11,535,052
Property, plant and equipment, net of accumulated depreciation of $955,765 at December 31, 2015 and $852,867 at September 30, 2015	561,912	572,107
Other assets:
Long term accounts receivables	1,500,000	1,500,000
Deposits	58,488	62,988
Goodwill	285,386	285,386
Intangible assets, net of accumulated amortization of $284,816 and $238,368 at December 31, 2015 and September 30, 2015, respectively	1,584,473	1,598,779
Total Assets	20,484,518	15,554,312
Current liabilities:
Accounts payable and accrued liabilities	2,110,995	2,385,006
Deferred revenue	57,526	282,050
Total current liabilities	2,168,521	2,667,056
Long term accounts payable	320,400	320,400
Total liabilities	$ 2,488,921	$ 2,987,456
Commitments and contingencies
Stockholders' Equity
Preferred stock value
Common stock, par value $0.001 per share; 500,000,000 shares authorized at December 31, 2015 and September 30, 2015; 24,072,092 and 21,504,578 shares issued and outstanding as of December 31, 2015 and September 30, 2015, respectively	$ 24,073	$ 21,505
Additional paid in capital	232,539,203	224,186,760
Accumulated deficit	(214,567,679)	(211,641,409)
Total stockholders' equity	17,995,597	12,566,856
Total Liabilities and Stockholders' Equity	$ 20,484,518	$ 15,554,312
Series A Preferred stock
Stockholders' Equity
Preferred stock value
Series B Preferred stock
Stockholders' Equity
Preferred stock value

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Allowance on accounts receivable (in dollars)	$ 7,140	$ 7,140
Accumulated depreciation on property, plant and equipment (in dollars)	955,765	852,867
Accumulated amortization on intangible assets (in dollars)	$ 284,816	$ 238,368
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	24,072,092	21,504,578
Common stock, shares outstanding	24,072,092	21,504,578
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	$ 1,324,114	$ 1,241,802
Operating expenses:
Selling, general and administrative	3,554,362	4,671,490
Research and development	471,934	278,288
Depreciation and amortization	218,346	109,726
Total operating expenses	4,244,642	5,059,504
LOSS FROM OPERATIONS	(2,920,528)	(3,817,702)
Other income (expense):
Interest income (expense), net	2,845	(31,875)
Other (expense) income, net	(8,587)	(3,685)
Loss on conversion of promissory notes		(980,842)
Loss on change in fair value of warrant liability		(2,994,540)
Net loss before provision for income taxes	$ (2,926,270)	$ (7,828,644)
Provision for income taxes
NET LOSS	$ (2,926,270)	$ (7,828,644)
Net loss per share-basic and diluted	$ (0.13)	$ (0.51)
Weighted average shares outstanding-
Basic and diluted	22,542,176	15,456,566

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (2,926,270)	$ (7,828,644)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	218,346	109,726
Stock based compensation expense	396,991	1,998,524
Change in fair value of warrant liability		2,994,540
Loss on conversion of promissory notes		980,842
Common stock issued for consulting services	58,120
Bad debt expense	10,000	2,779
Change in operating assets and liabilities:
Accounts receivable	(4,480)	(282,502)
Prepaid expenses and other current assets and deposits	71,896	(18,102)
Accounts payable and accrued liabilities	(320,825)	(253,997)
Deferred revenue	(224,524)	(59,001)
Net cash used in operating activities	(2,720,746)	(2,355,835)
Cash flows used in investing activities:
Purchase of property plant and equipment	(51,795)	(30,825)
Purchase of intangible assets	(14,301)
Net cash used in investing activities	(66,096)	(30,825)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	7,853,155	7,956,050
Proceeds from the exercise of warrants	4,410
Purchase and cancelation of previously issued warrants		(4,090,952)
Net cash provided by financing activities	7,857,565	3,865,098
Net increase in cash and cash equivalents	5,070,723	1,478,438
Cash and cash equivalents at beginning of period	7,312,184	1,393,132
Cash and cash equivalents at end of period	$ 12,382,907	$ 2,871,570
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest
Cash paid during period for taxes
Non-cash investing and financing activities:
Common stock issued for cashless exercise of options and warrants	$ 49
Property, plant and equipment acquired, and included in accounts payable	40,908	$ 181,104
Intangible assets acquired, and included in accounts payable	17,841
Issuance of options to settle accrued liability	$ 42,335

XML 17 R6.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

Business and Basis of Presentation

Revenue Recognition

Use of Estimates

Net Loss Per Share

For the three month periods ended December 31, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

	2015		2014
Warrants		7,324,727		4,470,502
Employee options		3,890,420		3,777,888
		11,215,147		8,248,390

Stock Based Compensation

Concentrations

XML 18 R7.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN	3 Months Ended
LIQUIDITY AND MANAGEMENT'S PLAN	Dec. 31, 2015
Liquidity And Management Plan [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN The Company has recurring net losses, which have resulted in an accumulated deficit of $214,567,679 as of December 31, 2015. The Company incurred a net loss of $2,926,270 and generated negative operating cash flow of $2,720,746 for the three month period ended December 31, 2015. However, the Company also has working capital of $14,325,738 as of December 31, 2015. At December 31, 2015 the Company had cash and cash equivalents of $12,382,907. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. Historically, the Company has financed its operations principally from the sale of equity securities. On November 23, 2015, the Company closed a registered direct public offering of common stock and a concurrent private placement of warrants to purchase common stock, for aggregate gross proceeds of approximately $8,750,000, before deducting placement agent fees and offering expenses (See Note D). The Company expects to finance operations and capital expenditures primarily through cash received from the November 2015 public offering and concurrent private placement as well as cash flows provided by operating activities provided that it will achieve a sufficient level of future revenues. The Company estimates that its cash and cash equivalents are sufficient to fund operations for the next twelve months. The Company may require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses. As a result of the Company's inability to file with the SEC certain audited historical financial statements relating to the assets of Vandalia Research, Inc. acquired in September 2015 by the date on which they were required to be filed, the Company is currently ineligible to use Form S-3, a streamlined registration form, to register securities for at least twelve calendar months and it would not regain the use of Form S-3 unless the Company was able to subsequently file these audited historical financial statements. Moreover, until the Company has filed the audited historical financial statements, it would be unable to use Form S-1 or other SEC forms to register securities as required for a public offering and would be unable to conduct offerings in private placements under Rule 505 or 506 of Regulation D to any purchasers who are not accredited investors. Therefore, until such time as the Company is able to conduct a public offering, if it determines it to be necessary or advisable to raise additional capital, the Company would need to issue securities in private placements to the extent permissible by law or seek other forms of financing. These alternatives generally entail greater total costs to the Company than a public offering of securities.

XML 19 R8.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

3 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at December 31, 2015 and September 30, 2015 are as follows:

	December 31, 2015 (unaudited)		September 30, 2015
Accounts payable	$	1,598,934	$	1,237,973
Accrued salaries payable		471,114		1,002,743
Other accrued expenses		40,947		144,290
Total	$	2,110,995	$	2,385,006

XML 20 R9.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK	3 Months Ended
CAPITAL STOCK	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	NOTE D - CAPITAL STOCK On November 23, 2015, the Company entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,500,000 shares of common stock at a price of $3.49 per share in a registered direct public offering. In a concurrent private placement, the Company sold warrants to purchase 1,250,000 shares of its common stock at a price of $0.01 per warrant, with an exercise price of $4.30 per share. The warrants will be exercisable beginning six months following the closing date of the private placement and will expire five years from the date on which they become exercisable. The warrants provide each warrant holder the right, at the warrant holder's election, to exercise by means of a cashless exercise feature. The gross proceeds to the Company from this registered direct offering and concurrent private placement were $8.75 million and net proceeds after deducting the placement agent fees and offering expenses were approximately $7.9 million. In connection with the closing of the registered direct public offering and the concurrent private placement, as partial compensation, on November 25, 2015, the Company granted warrants to purchase 50,000 shares of common stock to its placement agent. These warrants have an exercise price of $4.01 (115% of the public offering price), subject to adjustment as set forth therein, will be exercisable beginning six months following the closing date of the private placement and expire at 5:00 PM (Eastern Standard Time) on November 25, 2020. These warrants provide the placement agent the right, at the placement agent’s election, to exercise by means of a cashless exercise feature.

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

3 Months Ended

Dec. 31, 2015

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE E - STOCK OPTIONS AND WARRANTS

Warrants

Transactions involving warrants (see Note D) are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2015		6,027,654		$	3.54
Granted		1,300,000			4.29
Exercised		(1,260	)		(3.50	)
Cancelled or expired		(1,667	)		(10.74	)
Balance at December 31, 2015	$	7,324,727		$	3.67

Employee Stock Options

Transactions involving stock options issued to employees are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2015		3,458,905		$	4.74
Granted		531,523			3.04
Exercised		(75,000	)		(2.86	)
Cancelled or expired		(25,008	)		(4.20	)
Outstanding at December 31, 2015		3,890,420		$	4.26
Vested at December 31, 2015		2,819,006		$	4.23		$	0.97
Non-vested at December 31, 2015		1,071,415					$	0.87

	Three Months Ended December 31, 2015			Three Months Ended December 31, 2014
Stock price	$	3.04		$	2.84
Exercise price	$	3.04		$	2.84
Expected term, years		6.10			4.86
Dividend yield		—	%		—	%
Volatility		130	%		132	%
Risk free rate		1.8	%		1.58	%

XML 22 R11.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE G - COMMITMENTS AND CONTINGENCIES Operating Leases The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. Total rent expense for the three month periods ended December 31, 2015 and 2014 was $144,716 and $124,838, respectively. Employment Agreement The Company has an employment agreement with the Chief Executive Officer. Effective June 21, 2014, the Chief Executive Officer’s annual salary was voluntarily deferred by $50,000. This salary deferral will be accrued and repaid when the Company reaches $3,000,000 in sales for two consecutive quarters or the Company has net income at the end of any fiscal year. Effective January 1, 2015, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000. Effective January 1, 2016, the CEO's salary was increased to $400,000 pursuant to approval by the Compensation Committee of the Board of Directors. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

XML 23 R12.htm IDEA: XBRL DOCUMENT

ASSET PURCHASE AGREEMENT

3 Months Ended

Dec. 31, 2015

Asset Purchase Agreement [Abstract]

ASSET PURCHASE AGREEMENT

NOTE H - ASSET PURCHASE AGREEMENT

	Three month period
	ended
	December 31, 2014
Revenue	$	1,257,844

Net loss		(8,030,404	)

Basic and diluted loss per share	$	(0.52	)

XML 24 R13.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Policies)

3 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Business and Basis of Presentation

Revenue Recognition

Use of Estimates

Use of Estimates

Net Loss Per Share

For the three month periods ended December 31, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

	2015		2014
Warrants		7,324,727		4,470,502
Employee options		3,890,420		3,777,888
		11,215,147		8,248,390

Stock Based Compensation

Concentrations

Recent Accounting Pronouncements

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Schedule of anti-dilutive securities excluded from computation of earning per share

	2015		2014
Warrants		7,324,727		4,470,502
Employee options		3,890,420		3,777,888
		11,215,147		8,248,390

XML 26 R15.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

3 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

	December 31, 2015 (unaudited)		September 30, 2015
Accounts payable	$	1,598,934	$	1,237,973
Accrued salaries payable		471,114		1,002,743
Other accrued expenses		40,947		144,290
Total	$	2,110,995	$	2,385,006

XML 27 R16.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

3 Months Ended

Dec. 31, 2015

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of transactions involving warrants

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2015		6,027,654		$	3.54
Granted		1,300,000			4.29
Exercised		(1,260	)		(3.50	)
Cancelled or expired		(1,667	)		(10.74	)
Balance at December 31, 2015	$	7,324,727		$	3.67

Schedule of summary of transactions involving stock options issued to employees

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2015		3,458,905		$	4.74
Granted		531,523			3.04
Exercised		(75,000	)		(2.86	)
Cancelled or expired		(25,008	)		(4.20	)
Outstanding at December 31, 2015		3,890,420		$	4.26
Vested at December 31, 2015		2,819,006		$	4.23		$	0.97
Non-vested at December 31, 2015		1,071,415					$	0.87

Schedule of fair value of options granted

	Three Months Ended December 31, 2015			Three Months Ended December 31, 2014
Stock price	$	3.04		$	2.84
Exercise price	$	3.04		$	2.84
Expected term, years		6.10			4.86
Dividend yield		—	%		—	%
Volatility		130	%		132	%
Risk free rate		1.8	%		1.58	%

XML 28 R17.htm IDEA: XBRL DOCUMENT

ASSET PURCHASE AGREEMENT (Tables)

3 Months Ended

Dec. 31, 2015

Asset Purchase Agreement [Abstract]

Per forma information of company's financial results as if acquisition occurred

	Three month period
	ended
	December 31, 2014
Revenue	$	1,257,844

Net loss		(8,030,404	)

Basic and diluted loss per share	$	(0.52	)

XML 29 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) - shares	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	11,215,147	8,248,390
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	7,324,727	4,470,502
Employee options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	3,890,420	3,777,888

XML 30 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Accounting Policies [Abstract]
Deferred revenue	$ 57,526		$ 282,050
Revenue for government contract awards	504,349	$ 449,647
Long-term accounts receivable revenue recognized	$ 1,500,000		$ 1,500,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1)	3 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1)	Dec. 31, 2015 USD ($) Customer	Dec. 31, 2014 Customer	Sep. 30, 2015 USD ($)
Concentration Risk [Line Items]
Long term accounts receivables \| $	$ 1,500,000		$ 1,500,000
Customer Concentration Risk \| Total Revenue \| Three customers
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	73.00%
Number of customers	3
Customer Concentration Risk \| Total Revenue \| Two customers
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable		53.00%
Number of customers		2
Customer Concentration Risk \| Accounts Receivable \| Three customers
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	92.00%
Number of customers	3
Long term accounts receivables \| $	$ 1,500,000
Customer Concentration Risk \| Accounts Receivable \| Two customers
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable		74.00%
Number of customers		2

XML 32 R21.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 23, 2015	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
Liquidity And Management Plan [Abstract]
Accumulated deficit		$ (214,567,679)		$ (211,641,409)
Net loss		(2,926,270)	$ (7,828,644)
Operating cash flow		(2,720,746)	(2,355,835)
Working capital		14,325,738
Cash and cash equivalents		$ 12,382,907	$ 2,871,570	$ 7,312,184	$ 1,393,132
Gross proceeds from offering	$ 8,750,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Payables and Accruals [Abstract]
Accounts payable	$ 1,598,934	$ 1,237,973
Accrued salaries payable	471,114	1,002,743
Other accrued expenses	40,947	144,290
Total	$ 2,110,995	$ 2,385,006

XML 34 R23.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK (Detail Textuals) - USD ($)	1 Months Ended
CAPITAL STOCK (Detail Textuals) - USD ($)	Nov. 25, 2015	Nov. 23, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Gross proceeds from offering		$ 8,750,000
Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock called by warrants	50,000
Exercise price of warrants	$ 4.01
Exercise price percentage of public offering price	115.00%
Securities Purchase Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued		2,500,000
Share issued (Price per share)		$ 3.49
Gross proceeds from offering		$ 8,750,000
Net proceeds after deducting placement agent fees and offering expenses		$ 7,900,000
Securities Purchase Agreement \| Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock called by warrants		1,250,000
Share price		$ 0.01
Exercise price of warrants		$ 4.30

XML 35 R24.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details)	3 Months Ended
	Dec. 31, 2015 $ / shares shares
Number of Shares
Balance at October 1, 2015 \| shares	6,027,654
Granted \| shares	1,300,000
Exercised \| shares	(1,260)
Cancelled or expired \| shares	(1,667)
Balance, December 31, 2015 \| shares	7,324,727
Weighted Average Exercise Price Per Share
Balance at October 1, 2015 \| $ / shares	$ 3.54
Granted \| $ / shares	4.29
Exercised \| $ / shares	(3.50)
Cancelled or expired \| $ / shares	(10.74)
Balance, December 31, 2015 \| $ / shares	$ 3.67

XML 36 R25.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) - Employee Stock Options - Incentive Stock Plan 2005	3 Months Ended
	Dec. 31, 2015 $ / shares shares
Number of Shares
Outstanding at October 1, 2015 \| shares	3,458,905
Granted \| shares	531,523
Exercised \| shares	(75,000)
Cancelled or expired \| shares	(25,008)
Outstanding at December 31, 2015 \| shares	3,890,420
Vested at December 31, 2015 \| shares	2,819,006
Non-vested at December 31, 2015 \| shares	1,071,415
Weighted Average Exercise Price Per Share
Outstanding at October 1, 2015	$ 4.74
Granted	3.04
Exercised	(2.86)
Cancelled or expired	(4.20)
Outstanding at December 31, 2015	4.26
Vested at December 31, 2015	4.23
Aggregate Intrinsic Value, Vested at December 31, 2015	0.97
Aggregate Intrinsic Value, Non-vested at December 31, 2015	$ 0.87

XML 37 R26.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) - $ / shares	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock price	$ 3.04	$ 2.84
Exercise price	$ 3.04	$ 2.84
Expected term, years	6 years 1 month 6 days	4 years 10 months 10 days
Dividend yield
Volatility	130.00%	132.00%
Risk free rate	1.80%	1.58%

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) - Employee Stock Options - Incentive Stock Plan 2005	3 Months Ended
	Dec. 31, 2015 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option	8,833,333
Number of common stock shares that can be covered by awards made to any participant per period	833,334
Number of shares issued	269,752
Options to purchase shares under the 2005 Incentive Stock Plan	4,666,469

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 396,991	$ 1,998,524
Unrecorded compensation cost related to non-vested awards	$ 3,402,145
Weighted average period of non-vested awards options	2 years 4 months 6 days
Weighted average grant date fair value for options granted	$ 2.71
Employee Stock Options \| Employees, consultants and non-employee board of director members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	531,523
Employee Stock Options \| Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	160,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Detail Textuals)	1 Months Ended	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Detail Textuals)	Jun. 15, 2013 USD ($) ft²	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jan. 01, 2016 USD ($)	Jan. 01, 2015 USD ($)	Jun. 21, 2014 USD ($)
Commitments And Contingencies [Line Items]
Area of property under operating lease \| ft²	30,000
Extended operating lease for two additional period	3 years
Base rent during initial lease term per annum	$ 449,142
Total lease rental expenses		$ 144,716	$ 124,838
Chief Executive Officer \| Employment Agreement
Commitments And Contingencies [Line Items]
Deferred amount of salary					$ 50,000	$ 50,000
Threshold amount of sales for two consecutive quarters						$ 3,000,000
Chief Executive Officer \| Employment Agreement \| Subsequent Event
Commitments And Contingencies [Line Items]
Increased amount of salary				$ 400,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

ASSET PURCHASE AGREEMENT (Details)	3 Months Ended
ASSET PURCHASE AGREEMENT (Details)	Dec. 31, 2014 USD ($) $ / shares
Business Acquisition [Line Items]
Revenue	$ 1,257,844
Net loss	$ (8,030,404)
Basic and diluted loss per share \| $ / shares	$ (0.52)

XML 42 R31.htm IDEA: XBRL DOCUMENT

ASSET PURCHASE AGREEMENT (Detail Textuals) - Asset Purchase Agreement - Vandalia	Sep. 11, 2015 USD ($)
Business Acquisition [Line Items]
Purchase price for assets	$ 1,500,000
Amount held in escrow	500,000
Amount of indemnification claims paid	$ 350,000

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 36 165 1 false 20 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.adnas.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES SUMMARY OF ACCOUNTING POLICIES Notes 6 false false R7.htm 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN Sheet http://www.adnas.com/role/LiquidityAndManagementSPlan LIQUIDITY AND MANAGEMENT'S PLAN Notes 7 false false R8.htm 008 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 8 false false R9.htm 009 - Disclosure - CAPITAL STOCK Sheet http://www.adnas.com/role/CAPITALSTOCK CAPITAL STOCK Notes 9 false false R10.htm 010 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS STOCK OPTIONS AND WARRANTS Notes 10 false false R11.htm 011 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 012 - Disclosure - ASSET PURCHASE AGREEMENT Sheet http://www.adnas.com/role/AssetPurchaseAgreement ASSET PURCHASE AGREEMENT Notes 12 false false R13.htm 013 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 13 false false R14.htm 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables SUMMARY OF ACCOUNTING POLICIES (Tables) Tables http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES 14 false false R15.htm 015 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES 15 false false R16.htm 016 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS 16 false false R17.htm 017 - Disclosure - ASSET PURCHASE AGREEMENT (Tables) Sheet http://www.adnas.com/role/ASSETPURCHASEAGREEMENTTables ASSET PURCHASE AGREEMENT (Tables) Tables http://www.adnas.com/role/AssetPurchaseAgreement 17 false false R18.htm 018 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesSummaryOfPotentialStockIssuancesUnderVariousOptionsAndWarrantsDetails SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Details 18 false false R19.htm 019 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesDetailTextuals SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 19 false false R20.htm 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailTextuals1 SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 20 false false R21.htm 021 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Sheet http://www.adnas.com/role/LiquidityAndManagementSPlanDetailTextuals LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Details http://www.adnas.com/role/LiquidityAndManagementSPlan 21 false false R22.htm 022 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESSummaryOfAccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Details 22 false false R23.htm 023 - Disclosure - CAPITAL STOCK (Detail Textuals) Sheet http://www.adnas.com/role/CapitalStockDetailTextuals CAPITAL STOCK (Detail Textuals) Details http://www.adnas.com/role/CAPITALSTOCK 23 false false R24.htm 024 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingWarrantsDetails STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Details 24 false false R25.htm 025 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingStockOptionsIssuedToEmployeesDetails1 STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) Details 25 false false R26.htm 026 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsSummaryOfValueOfOptionsGrantedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Details 26 false false R27.htm 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) Details 27 false false R28.htm 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals1 STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) Details 28 false false R29.htm 029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIESDetailTextuals COMMITMENTS AND CONTINGENCIES (Detail Textuals) Details http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES 29 false false R30.htm 030 - Disclosure - ASSET PURCHASE AGREEMENT (Details) Sheet http://www.adnas.com/role/Assetpurchaseagreementdetails ASSET PURCHASE AGREEMENT (Details) Details http://www.adnas.com/role/ASSETPURCHASEAGREEMENTTables 30 false false R31.htm 031 - Disclosure - ASSET PURCHASE AGREEMENT (Detail Textuals) Sheet http://www.adnas.com/role/Assetpurchaseagreementdetailtextuals ASSET PURCHASE AGREEMENT (Detail Textuals) Details http://www.adnas.com/role/ASSETPURCHASEAGREEMENTTables 31 false false All Reports Book All Reports apdn-20151231.xml apdn-20151231.xsd apdn-20151231_cal.xml apdn-20151231_def.xml apdn-20151231_lab.xml apdn-20151231_pre.xml true true ZIP 49 0001571049-16-011637-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-16-011637-xbrl.zip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Ǚ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end